Literature DB >> 7594797

Candidemia in non-neutropenic patients with an intravenous hyperalimentation catheter: good prognosis of Candida parapsilosis infection.

S Kataoka1, M Kashiwa, K Saku, N Handa, H Akiyama.   

Abstract

Positive blood cultures reported between 1986 and 1993 at the Tokyo Metropolitan Komagome Hospital were evaluated and all patients with an intravenous hyperalimentation catheter who developed candidemia, a total of 94 patients, were analyzed further, while patients with neutropenia were excluded. The primary diagnosis was malignancy in 87.2% of the cases, and Candida albicans and C. parapsilosis were the main organisms detected. A total of 17 patients died from candidemia. The patients who were positive for C. parapsilosis, however, all survived in spite of the fact that their main treatment was only removal of the catheter (20/32 cases), while eight of 25 patients who developed fungemia due to C. albicans died from the fungemia (p = 0.001). There were no significant differences in their risk factors. Because of the better outcome for the patients who developed candidemia due to C. parapsilosis, we might be able to consider less aggressive treatment for such patients.

Entities:  

Mesh:

Year:  1995        PMID: 7594797     DOI: 10.11150/kansenshogakuzasshi1970.69.969

Source DB:  PubMed          Journal:  Kansenshogaku Zasshi        ISSN: 0387-5911


  2 in total

1.  Candidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992-1994. Fungal Disease Registry of the Canadian Infectious Disease Society.

Authors:  D L Yamamura; C Rotstein; L E Nicolle; S Ioannou
Journal:  CMAJ       Date:  1999-02-23       Impact factor: 8.262

2.  Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.

Authors:  A L Colombo; J Perfect; M DiNubile; K Bartizal; M Motyl; P Hicks; R Lupinacci; C Sable; N Kartsonis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-07-23       Impact factor: 3.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.